HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Huda Beauty Flouts US Law With Neon Obsession, Ahem, ‘Multiuse Pigments’ – Class Action

Executive Summary

Huda Beauty clearly intends for its Neon Obsession color palettes to be used as eyeshadow, despite a “hidden disclaimer” contraindicating the products for eye-area use, according to the plaintiff in a proposed class action filed in California’s Central District.

You may also be interested in...



Neon Eye Makeup Not Intended For Eyes? Internet Reacts To Seeming Labeling-Marketing Contradictions

Recent discussion in the media about the rise of neon eyeshadow palettes, seemingly without any of the necessary FDA-approved colorants to make them possible, has given rise to safety and regulatory compliance questions. Naturally, some consumers are outraged, while others seem reluctant to raise a stink to the detriment of makeup options.

EWG Endorses Mineral Sunscreens, Avobenzone And UVA-Protective Chemicals Stranded In Europe

Three-fourths of sunscreens marketed in the US offer “inferior” protection or contain “worrisome” chemicals, according to the Environmental Working Group’s 2020 Sunscreen Guide. The guide shows overwhelming preference for mineral over chemical sunscreens, while also suggesting that Americans would be better off if UVA-protective chemical filters in Europe were allowed stateside.

COVID Who? CBD Leader Charlotte’s Web Maintains FY 2020 Guidance Of Growth Up To 20%

Charlotte’s Web is strengthening its DTC lead while growing its brick-and-mortar retail business, accelerating its pet product distribution and working to close its Abacus Health acquisition announced in March. The Boulder, CO-based CBD product manufacturer posted a 1% decline in net sales for the first quarter, but expects a rapid escalation in the second half of the year.

Topics

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel